CME Lunch Symposium · Friday, October 26, 2018 · 12:00 – 1:15pm
Identifying, Diagnosing and Managing Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life
Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.
In this symposium, experts will provide participants with data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.
After completing this activity, the participant should be better able to:
Describe the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life
Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID
Discuss the updated ACC/AHA/HFSA recommended guidelines for the management of iron deficiency in patients with HF
Review evidence from major clinical trials assessing the efficacy and safety of iron supplementation in HF patients to improve patient outcomes and reduce HF hospitalizations